208 related articles for article (PubMed ID: 22748473)
1. Immunohistochemical panel for distinguishing esophageal adenocarcinoma from squamous cell carcinoma: a combination of p63, cytokeratin 5/6, MUC5AC, and anterior gradient homolog 2 allows optimal subtyping.
DiMaio MA; Kwok S; Montgomery KD; Lowe AW; Pai RK
Hum Pathol; 2012 Nov; 43(11):1799-807. PubMed ID: 22748473
[TBL] [Abstract][Full Text] [Related]
2. A combination of cytokeratin 5/6, p63, p40 and MUC5AC are useful for distinguishing squamous cell carcinoma from adenocarcinoma of the cervix.
Li H; Jing X; Yu J; Liu J; Zhang T; Chen S; Zhang X
Diagn Pathol; 2020 Aug; 15(1):104. PubMed ID: 32843061
[TBL] [Abstract][Full Text] [Related]
3. Esophagogastric Junction Carcinomas - Discriminating Histological Types Through Immunohistochemistry.
Mochizuki K; Kondo T; Oishi N; Tahara I; Inoue T; Kasai K; Nakazawa T; Katoh R
Anticancer Res; 2017 Dec; 37(12):6855-6861. PubMed ID: 29187465
[TBL] [Abstract][Full Text] [Related]
4. SOX2 is highly expressed in squamous cell carcinomas of the gastrointestinal tract.
Long KB; Hornick JL
Hum Pathol; 2009 Dec; 40(12):1768-73. PubMed ID: 19716157
[TBL] [Abstract][Full Text] [Related]
5. p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma.
Bishop JA; Teruya-Feldstein J; Westra WH; Pelosi G; Travis WD; Rekhtman N
Mod Pathol; 2012 Mar; 25(3):405-15. PubMed ID: 22056955
[TBL] [Abstract][Full Text] [Related]
6. A study of ΔNp63 expression in lung non-small cell carcinomas.
Nonaka D
Am J Surg Pathol; 2012 Jun; 36(6):895-9. PubMed ID: 22367298
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens.
Rekhtman N; Ang DC; Sima CS; Travis WD; Moreira AL
Mod Pathol; 2011 Oct; 24(10):1348-59. PubMed ID: 21623384
[TBL] [Abstract][Full Text] [Related]
8. The Value of Cytokeratin 5/6, p63 and Thyroid Transcription Factor-1 in Adenocarcinoma, Squamous Cell Carcinoma and Non-Small-Cell Lung Cancer of the Lung.
Argon A; Nart D; Veral A
Turk Patoloji Derg; 2015; 31(2):81-8. PubMed ID: 25944390
[TBL] [Abstract][Full Text] [Related]
9. Best immunohistochemical panel in distinguishing adenocarcinoma from squamous cell carcinoma of lung: tissue microarray assay in resected lung cancer specimens.
Kim MJ; Shin HC; Shin KC; Ro JY
Ann Diagn Pathol; 2013 Feb; 17(1):85-90. PubMed ID: 23040737
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of napsin A, cytokeratin 5/6, p63, and thyroid transcription factor 1 in adenocarcinoma versus squamous cell carcinoma of the lung.
Whithaus K; Fukuoka J; Prihoda TJ; Jagirdar J
Arch Pathol Lab Med; 2012 Feb; 136(2):155-62. PubMed ID: 22288962
[TBL] [Abstract][Full Text] [Related]
11. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma.
Ordóñez NG
Am J Surg Pathol; 1998 Oct; 22(10):1215-21. PubMed ID: 9777983
[TBL] [Abstract][Full Text] [Related]
12. Immunoreactivity of cytokeratins (CK7, CK20) and mucin peptide core antigens (MUC1, MUC2, MUC5AC) in adenocarcinomas, normal and metaplastic tissues of the distal oesophagus, oesophago-gastric junction and proximal stomach.
Flucke U; Steinborn E; Dries V; Mönig SP; Schneider PM; Thiele J; Hölscher AH; Dienes HP; Baldus SE
Histopathology; 2003 Aug; 43(2):127-34. PubMed ID: 12877727
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2.
Chu PG; Schwarz RE; Lau SK; Yen Y; Weiss LM
Am J Surg Pathol; 2005 Mar; 29(3):359-67. PubMed ID: 15725805
[TBL] [Abstract][Full Text] [Related]
14. The use of p63 as an effective immunomarker in the diagnosis of pulmonary squamous cell carcinomas on de-stained bronchial lavage cytological smears.
Uke M; Rekhi B; Ajit D; Jambhekar NA
Cytopathology; 2010 Feb; 21(1):56-63. PubMed ID: 19744186
[TBL] [Abstract][Full Text] [Related]
15. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis.
Nicholson AG; Gonzalez D; Shah P; Pynegar MJ; Deshmukh M; Rice A; Popat S
J Thorac Oncol; 2010 Apr; 5(4):436-41. PubMed ID: 20068475
[TBL] [Abstract][Full Text] [Related]
16. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens.
Loo PS; Thomas SC; Nicolson MC; Fyfe MN; Kerr KM
J Thorac Oncol; 2010 Apr; 5(4):442-7. PubMed ID: 20195168
[TBL] [Abstract][Full Text] [Related]
17. Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders.
Glickman JN; Yang A; Shahsafaei A; McKeon F; Odze RD
Hum Pathol; 2001 Nov; 32(11):1157-65. PubMed ID: 11727253
[TBL] [Abstract][Full Text] [Related]
18. Cytokeratin expression in adenocarcinomas of the esophagogastric junction: a comparative study of adenocarcinomas of the distal esophagus and of the proximal stomach.
Taniere P; Borghi-Scoazec G; Saurin JC; Lombard-Bohas C; Boulez J; Berger F; Hainaut P; Scoazec JY
Am J Surg Pathol; 2002 Sep; 26(9):1213-21. PubMed ID: 12218578
[TBL] [Abstract][Full Text] [Related]
19. P63 expression in lung carcinoma: a tissue microarray study of 408 cases.
Au NH; Gown AM; Cheang M; Huntsman D; Yorida E; Elliott WM; Flint J; English J; Gilks CB; Grimes HL
Appl Immunohistochem Mol Morphol; 2004 Sep; 12(3):240-7. PubMed ID: 15551738
[TBL] [Abstract][Full Text] [Related]
20. Utility of 10 immunohistochemical markers including novel markers (desmocollin-3, glypican 3, S100A2, S100A7, and Sox-2) for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the Lung.
Tsuta K; Tanabe Y; Yoshida A; Takahashi F; Maeshima AM; Asamura H; Tsuda H
J Thorac Oncol; 2011 Jul; 6(7):1190-9. PubMed ID: 21623236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
